Actively Recruiting
Cardiovascular-Renal Adverse Outcome Risk Assessment System for Coronary Heart Disease Combined With Chronic Kidney Disease Based on Targeted Lipid Metabolomics
Led by China-Japan Friendship Hospital · Updated on 2024-04-25
470
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating coronary heart disease (CHD) combined with chronic kidney disease (CKD), conditions that often occur together and lead to poor health outcomes. Despite controlling traditional risk factors, improving results for these patients has been challenging. This study focuses on new lipid metabolites linked to CHD and CKD progression and aims to develop a risk prediction tool for adverse cardiovascular and kidney outcomes using advanced metabolomics analysis and clinical data. The study involves collecting fasting blood samples from participants to analyze targeted lipid metabolism using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system. This observational study will follow patients for 12 months to track cardiovascular adverse events and renal composite endpoint events. Researchers will use metabolomics data and clinical information to identify lipid profiles associated with disease progression and create a clinically useful risk assessment model. Participants will be adults aged 18 to 80 with diagnosed CHD confirmed by coronary angiography and known kidney function status. During the study, blood samples will be collected for metabolomics research, and patients will be monitored for cardiovascular and kidney outcomes over a year. Safety and overall health will also be evaluated by tracking all-cause mortality, repeat revascularization, and bleeding incidents, providing insight into disease progression and prognosis.
CONDITIONS
Brief Title
Cardiovascular-Renal Adverse Prognosis Assessment System for Coronary Heart Disease With Chronic Kidney Disease Based on Metabolomics
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 80 years old
- Diagnosed with coronary heart disease during hospitalization through coronary angiography, including STEMI, NST-ACS, or stable angina pectoris
- Known renal function status
- Chronic kidney disease defined as eGFR less than 60 ml/min/1.73 m2 for more than 3 months or eGFR greater or equal to 60 ml/min/1.73 m2 with urinary albumin-to-creatinine ratio of 30 mg/g or higher
You will not qualify if you...
- Pregnancy or lactation
- Severe valve disease or severe mechanical complications requiring surgery
- Severe psychiatric illness or other conditions preventing follow-up
- Severe hematologic disorders or advanced malignant tumors
- History of kidney transplantation or long-term dialysis
- Severe liver disease (Child-Pugh class C)
- Acute renal failure dialysis within 12 weeks before screening
- Severe chronic lung disease needing long-term ventilation or lung transplant
- Life expectancy less than 1 year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants provide fasting peripheral venous blood samples for targeted lipid metabolomics analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
1 visit (in-person)
Duration - 12 months
Participants are followed for 12 months to monitor the incidence of cardiovascular and renal adverse events, as well as other health outcomes.
Follow-up visits as scheduled during the 12-month period
Trial Site Locations
Total: 1 location
1
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
C
Chen Qiang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here